View Post

UH Cancer Center, HMSA collaborate to fight breast cancer

In Clinical Trials by Barbara Jacoby

By: Nana Ohkawa From: hawaii.edu The University of Hawaiʻi Cancer Center is working with the Hawaiʻi Medical Service Association (HMSA) to conduct a first-of-its-kind clinical trial that could lead to less anxiety for patients with metastatic breast cancer, improved quality of life for patients and their families and lower costs for the community. These changes would result from optimizing the …

View Post

Cancer: ‘Off-the-shelf’ stem cell treatment enters clinical trial

In Clinical Trials by Barbara Jacoby

By: Yella Hewings-Martin PhD From: medicalnewstoday.com In a first-of-its-kind trial in the United States, researchers are testing a stem cell-derived natural killer cell immunotherapy in people with incurable cancer. Cancer follows heart disease as the second biggest killer worldwide. In the United States, an estimated 606,880 people will die due to cancer in 2019. With the advent of immunotherapy, researchers …

View Post

Rakuten Medical’s ASP-1929 photoimmunotherapy for head and neck cancers to be designated under the Sakigake Designation System for its potential innovativeness and effectiveness

In Clinical Trials by Barbara Jacoby

Source: Rakuten Medical, Inc. From: prnewswire.com Based on its exclusive license related to photoimmunotherapy, Rakuten Medical Inc., which is developing a cancer therapy to target cancer cells, announced that ASP-1929 received Sakigake designation under the Sakigake Designation System*, which is a Fast Track designation from the Japanese Ministry of Health, Labour, and Welfare as a treatment for head and neck …

View Post

UC San Diego Health treats 1st cancer patient with stem-cell derived natural killer cells

In Clinical Trials by Barbara Jacoby

Source: University of California-SanDiego From: eurekalert.org After 10 years in remission, Derek Ruff’s cancer returned, this time as stage IV colon cancer. Despite aggressive rounds of chemotherapy, palliative radiotherapy and immunotherapy, his disease progressed. In February 2019, as part of a phase I clinical trial at Moores Cancer Center at UC San Diego Health, Ruff became the first patient in …

View Post

Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR

In Clinical Trials by Barbara Jacoby

From: businesswire.com Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. MSC-1 is a humanized antibody against a soluble cytokine called LIF (see “About LIF” below). LIF plays a multi-faceted …

View Post

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

In Clinical Trials by Barbara Jacoby

Source: Sorrento Therapeutics, Inc. From: apnews.com Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. This Phase 1 dose-escalation study, approved by the South Korean Ministry …

View Post

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body.1 Men are considered hormone …

View Post

Implantable cancer vaccine

In Clinical Trials by Barbara Jacoby

A small implant can recruit and reprogram a patient’s own immune cells “on site” to kill cancer cells The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth …

View Post

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer

In Clinical Trials by Barbara Jacoby

From: thelancet.com A randomised, non-inferiority, open-label, phase 3 trial Background To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. Methods This randomised, non-inferiority, …

View Post

Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …